Human IL-29/IFN-lambda 1 Antibody

Catalog # Availability Size / Price Qty
MAB15981-SP
MAB15981-500
MAB15981-100
Human IL-29/IFN-lambda 1 Antibody in Data
1 Image
Product Details
Citations (9)
FAQs
Supplemental Products
Reviews (1)

Human IL-29/IFN-lambda 1 Antibody Summary

Species Reactivity
Human
Specificity
Detects human IL-29/IFN-lambda 1 in ELISAs. In sandwich immunoassays, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL‑28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN‑ beta 1A.
Source
Monoclonal Mouse IgG2A Clone # 247801
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human IL-29/IFN-lambda 1
Gly20-Thr200
Accession # Q8IU54
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration
Sample

IL-29/IFN-lambda 1 Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human IL‑29/IFN‑ lambda 1 Biotinylated Antibody (Catalog # BAF1598)

Standard: Recombinant Human IL-29/IFN-lambda 1 Protein (Catalog # 1598-IL)

Neutralization
Measured by its ability to neutralize IL‑29/IFN‑ lambda 1 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 40 ng/mL Recombinant Human IL‑29/IFN‑ lambda 1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Neutralization IL‑29/IFN‑ lambda 1 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑29/IFN‑ lambda 1 Antibody. View Larger

IL‑29/IFN‑ lambda 1 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑29/IFN‑ lambda 1 Antibody. Recombinant Human IL-29/IFN-?1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-29/IFN-?1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anri-Human IL-29/IFN-?1 Monoclonal Antibody (Catalog # MAB15981). The ND50is typically 1-4 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-29/IFN-lambda 1

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and the type I IFN family (15‑19% aa sequence identity) (1‑3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

References
  1. Vilcek, J. (2003) Nature Immunol. 4:8.
  2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Long Name
Interleukin 29
Entrez Gene IDs
282618 (Human)
Alternate Names
cytokine Zcyto21; IFNL1; IFN-lambda 1; IFN-lambda-1; IL29; IL-29; interferon lambda-1; interferon, lambda 1; interleukin 29 (interferon, lambda 1); interleukin-29; ZCYTO21

Product Datasheets

Citations for Human IL-29/IFN-lambda 1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

9 Citations: Showing 1 - 9
Filter your results:

Filter by:

  1. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
    Authors: V Oke, I Gunnarsson, J Dorschner, S Eketjäll, A Zickert, TB Niewold, E Svenungsso
    Arthritis Res. Ther., 2019;21(1):107.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Capture
  2. IFN-?1 with Th17 axis cytokines and IFN-? define different subsets in systemic lupus erythematosus (SLE)
    Authors: V Oke, S Brauner, A Larsson, J Gustafsson, A Zickert, I Gunnarsson, E Svenungsso
    Arthritis Res. Ther., 2017;19(1):139.
    Species: Human
    Sample Types: Serum
  3. Interferon (IFN)-? is a potential mediator in lupus nephritis
    Authors: Iva Gunnarsson
    Lupus Sci Med, 2016;3(1):e000170.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Development (Capture)
  4. Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.
    Authors: Villenave R, Broadbent L, Douglas I, Lyons J, Coyle P, Teng M, Tripp R, Heaney L, Shields M, Power U
    J Virol, 2015;89(24):12309-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  5. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation.
    Authors: Persson B, Jaffe A, Fearns R, Danahay H
    PLoS ONE, 2014;9(7):e102368.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  6. Direct, interferon-independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection.
    Authors: Brownell J, Bruckner J, Wagoner J, Thomas E, Loo Y, Gale M, Liang T, Polyak S
    J Virol, 2014;88(3):1582-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells.
    Authors: Stone, Amy E L, Giugliano, Silvia, Schnell, Gretja, Cheng, Linling, Leahy, Katelyn, Golden-Mason, Lucy, Gale, Michael, Rosen, Hugo R
    PLoS Pathog, 2013;9(4):e1003316.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  8. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells.
    Authors: Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute S, Garrigues U, Doyle S, Donnelly R, Kotenko S, Fitzgerald-Bocarsly P
    J Immunol, 2012;189(6):2735-45.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.
    Authors: Brownell J, Wagoner J, Lovelace E, Thirstrup D, Mohar I, Smith W, Giugliano S, Li K, Crispe I, Rosen H, Polyak S
    J Hepatol, 0;59(4):701-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Mouse IgG2A Isotype Control

Reconstitution Buffers

Secondary Antibodies

Reviews for Human IL-29/IFN-lambda 1 Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human IL-29/IFN-lambda 1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human IL-29/IFN-lambda 1 Antibody
By Anonymous on 06/01/2018
Application: ELISA Sample Tested: Serum Species: Human

This antibody was used as the capture in a sandwich ELISA with BAF1598 as the detection.